Sun Pyrite 17x

Dosage for Ferrous Disulfide as an allergenic extract is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no 'standard' dose.

• Diagnostic Testing: Typically, a single drop of a specific concentration (e.g., 1:10 or 1:100 w/v) is applied during a prick test. For intradermal testing, 0.02 mL to 0.05 mL of a highly diluted solution is injected.
• Therapeutic Immunotherapy: Dosing follows a 'Build-up Phase' and a 'Maintenance Phase.'
• Build-up Phase: Starts with a very low dose (often 0.1 mL of a 1:100,000 dilution) and increases weekly or bi-weekly.
• Maintenance Phase: Once the 'top dose' is reached (the highest dose tolerated without a systemic reaction), injections are spaced out to every 2–4 weeks.

Pediatric dosing follows the same principles of individualization as adult dosing. However, extreme caution is required for children under the age of 5 due to the difficulty of communicating early symptoms of systemic reactions. Dose increments during the build-up phase may be more conservative in the pediatric population.

Renal Impairment

No specific dose adjustments are provided for renal impairment due to the minimal systemic absorption of the extract. However, patients with compromised renal function should be monitored for fluid balance if receiving large volumes of parenteral fluids concurrently.

Hepatic Impairment

No dosage adjustments are typically required for hepatic impairment, as Ferrous Disulfide does not undergo significant hepatic metabolism.

Elderly Patients

Elderly patients may have a higher risk of adverse cardiovascular events if a systemic reaction (anaphylaxis) occurs. Clinicians may opt for slower dose escalation and more frequent monitoring of vital signs during administration.

• Administration Site: Therapeutic injections must be given subcutaneously, usually in the posterior aspect of the upper arm. They must NEVER be given intravenously.
• Observation Period: Patients MUST remain in the medical office for at least 30 minutes after receiving an injection. Most fatal systemic reactions occur within this window.
• Storage: Extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the proteins in the extract and alter potency.
• Consistency: Use the same manufacturer for the entire course of treatment if possible, as 'non-standardized' means potency varies between brands.

If a dose in the immunotherapy schedule is missed, do not double the next dose. If the lapse is brief (e.g., 1 week), the same dose may be repeated. If the lapse is significant (e.g., several weeks), the dose must be reduced to a previous safe level to prevent a systemic reaction due to loss of tolerance.

An overdose of an allergenic extract manifests as an immediate systemic allergic reaction or anaphylaxis.

• Signs: Hives, swelling of the throat, wheezing, rapid pulse, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) is the first-line treatment. Seek emergency medical services (911) immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Ferrous Disulfide as an extract will experience local reactions at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Erythema: Redness at the injection site that may appear within minutes and last for several hours.
• Local Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is larger than the size of a half-dollar (approx. 3 cm), it should be reported to the clinician, as it may indicate the need for a dose adjustment.
• Pruritus: Intense itching at the site of injection or testing.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after the injection. These are often treated with cold compresses and oral antihistamines.
• Fatigue: Some patients report feeling unusually tired for the remainder of the day following an immunotherapy injection.
• Mild Rhinitis: Brief periods of sneezing or nasal congestion shortly after administration.

• Systemic Urticaria: Hives appearing on parts of the body distant from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Vasovagal Reactions: Fainting or lightheadedness, often triggered by the needle stick rather than the medication itself.

> Warning: Stop taking Ferrous Disulfide and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or difficulty breathing.
• Laryngeal Edema: A feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing.
• Hypotension: A sudden drop in blood pressure, which may feel like extreme dizziness or passing out.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Generalized Seizures: Rare, but can occur in the context of severe systemic shock.

There is no evidence that long-term use of Ferrous Disulfide allergenic extracts leads to organ toxicity or malignancy. The primary long-term risk is the development of new sensitivities, though immunotherapy is generally intended to prevent the 'allergic march.' In rare cases, chronic local irritation can lead to subcutaneous nodules (small, hard lumps) at the injection sites.

While Ferrous Disulfide specifically may not have a unique black box warning, the class of Allergenic Extracts carries a general warning regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at higher risk. Injections should only be administered in a healthcare setting equipped with emergency equipment and personnel trained to treat anaphylaxis. Patients should be observed for at least 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider.

Ferrous Disulfide, as a non-standardized extract, possesses a variable potency that requires cautious clinical handling. It is not interchangeable with other iron-containing supplements or different brands of extracts. Patients must be stable and healthy at the time of administration; any acute illness, especially those involving the respiratory tract, should result in a postponement of the dose.

No specific FDA black box warning exists solely for the chemical 'Ferrous Disulfide,' but as an Allergenic Extract, it falls under the mandatory class warning for anaphylaxis. This warning emphasizes that the risk of death is higher in patients with poorly controlled asthma or those taking certain medications like beta-blockers, which can complicate the treatment of an allergic reaction.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. All patients must be screened for a history of severe reactions to similar compounds.
• Asthma Stability: Patients with asthma must have their lung function assessed (e.g., Peak Flow or FEV1) before receiving an injection. If the patient is experiencing an asthma flare, the injection must be withheld.
• Injection Technique: Accidental intravenous injection can cause immediate, severe systemic reactions. Aspiration before injection is mandatory to ensure the needle is not in a blood vessel.

• Pre-injection Check: Assessment of current health status, any new medications, and the size of the reaction from the previous dose.
• Post-injection Observation: Mandatory 30-minute wait time in the clinic.
• Lung Function: Periodic spirometry for asthmatic patients.
• Skin Checks: Monitoring for the development of chronic skin changes at injection sites.

Patients should avoid driving or operating heavy machinery for at least 30 minutes after administration. If a vasovagal reaction or mild systemic reaction occurs, the patient should not drive until symptoms have completely resolved and they have been cleared by a healthcare professional.

Alcohol consumption should be avoided on the day of the injection. Alcohol can cause vasodilation, which may theoretically increase the rate of absorption of the extract from the injection site, potentially increasing the risk of a systemic reaction.

If a patient experiences a severe systemic reaction, the risks and benefits of continuing Ferrous Disulfide therapy must be re-evaluated. If discontinued, no tapering is required as there is no physical dependence associated with allergenic extracts.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ferrous Disulfide.

• Beta-Blockers (Non-selective and Selective): These medications (e.g., propranolol, metoprolol) are contraindicated or used with extreme caution. They can increase the severity of anaphylaxis and, crucially, make the patient resistant to the effects of epinephrine, the primary treatment for a severe reaction.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., lisinopril) may be at a higher risk for more severe systemic reactions to allergenic extracts.
• MAO Inhibitors (MAOIs): Medications like phenelzine can potentiate the effects of sympathomimetics used to treat reactions, leading to hypertensive crises.
• Tricyclic Antidepressants: Similar to MAOIs, these can interfere with the management of a systemic reaction.

• Immunosuppressants: Drugs like prednisone or cyclosporine may reduce the efficacy of the immunotherapy by suppressing the very immune response the extract is trying to modulate.
• Other Immunotherapies: Receiving multiple types of immunotherapy simultaneously increases the cumulative risk of a systemic reaction.

• High-Histamine Foods: Consuming foods high in histamine (aged cheeses, fermented products) shortly before or after an injection may theoretically lower the threshold for an allergic reaction in highly sensitive individuals.
• Caffeine: Excessive caffeine can increase heart rate and may complicate the assessment of a patient's vital signs during a suspected reaction.

• St. John's Wort: May interact with medications used to treat anaphylaxis.
• Iron Supplements: While Ferrous Disulfide is an iron compound, its use as an extract is for immunological purposes. However, excessive oral iron intake should be discussed with a doctor to avoid total iron overload, though the amount in an extract is negligible.

• Skin Tests: Antihistamines (H1 blockers) must be stopped several days before skin testing with Ferrous Disulfide, as they will suppress the wheal and flare response, leading to a false-negative result.
• Serum Iron Tests: The minute amount of iron in a Ferrous Disulfide extract is unlikely to affect serum iron or ferritin levels.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Previous Severe Anaphylaxis: Patients who have had a life-threatening reaction to Ferrous Disulfide or any component of the extract should not receive it again.
• Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted value or those with frequent acute exacerbations are at an unacceptable risk for fatal bronchospasm during a reaction.
• Active Malignancy: Immunotherapy is generally avoided in patients with active cancer to prevent further immune system complications.
• Severe Immunodeficiency: Patients with compromised immune systems may not respond to the therapy and may face increased risks.

• Pregnancy: While not an absolute contraindication for those already on a stable maintenance dose, starting Ferrous Disulfide immunotherapy during pregnancy is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia.
• Autoimmune Disorders: Conditions like Lupus or Rheumatoid Arthritis require a careful risk-benefit analysis, as the extract could potentially flare the underlying condition.
• Beta-Blocker Therapy: As noted in interactions, this significantly complicates the safety profile.

Patients with known sensitivities to other iron salts or sulfur-containing compounds should be approached with extreme caution. While 'sulfa drug' allergies (sulfonamides) are chemically different from elemental sulfur in Ferrous Disulfide, clinical vigilance is still advised.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ferrous Disulfide.

Ferrous Disulfide is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not teratogenicity (birth defects) but rather the potential for maternal anaphylaxis. A severe allergic reaction can cause a sudden drop in maternal blood pressure and uterine contraction, leading to fetal hypoxia (lack of oxygen) or miscarriage. Healthcare providers generally recommend against initiating new immunotherapy during pregnancy, though maintenance doses may be continued if the benefit outweighs the risk.

It is not known whether the components of Ferrous Disulfide extract are excreted in human milk. Because the systemic absorption is minimal, the risk to the nursing infant is considered low. However, the decision to continue treatment while breastfeeding should be made in consultation with a physician, weighing the mother's need for treatment against potential infant risks.

Safety and effectiveness in children under the age of 5 have not been established. In older children, Ferrous Disulfide extracts are used similarly to adults, but with closer monitoring. Children may be less able to articulate the early 'aura' of an impending allergic reaction (such as an itchy palate or chest tightness), making them more vulnerable to sudden systemic events.

Clinical studies of allergenic extracts typically do not include sufficient numbers of subjects aged 65 and over. In elderly patients, the risk of cardiovascular complications during a systemic reaction is significantly higher. Pre-existing conditions like coronary artery disease or hypertension make the use of epinephrine more dangerous. Dose escalation should be performed with extreme caution in this population.

No specific studies have been conducted in patients with renal impairment. Given the reticuloendothelial clearance of the mineral components, standard renal impairment is not expected to significantly alter the drug's safety profile, provided the patient is not in a state of acute fluid overload.

There are no specific dose adjustments for patients with hepatic impairment. However, since the liver produces many of the proteins involved in the inflammatory cascade, patients with severe end-stage liver disease may have unpredictable responses to allergenic extracts.

> Important: Special populations require individualized medical assessment.

Ferrous Disulfide acts as an exogenous antigen. In diagnostic applications, it facilitates the Type I Hypersensitivity reaction by binding to IgE on mast cells. In therapeutic applications, it induces immunological tolerance. This involves the induction of T-regulatory cells (CD4+ CD25+ Foxp3+), which suppress the allergic response. There is also a notable 'isotype switch' where the body increases the production of IgG4 antibodies. These IgG4 antibodies act as 'blocking antibodies,' competing with IgE for the allergen binding sites, thereby preventing the allergic cascade.

The onset of the diagnostic effect (skin test) is rapid, occurring within 15–20 minutes. The therapeutic effect (desensitization) is slow, often taking 6 to 12 months of consistent dosing to reach clinical significance. The duration of the effect can last for several years after a successful 3-to-5-year course of immunotherapy.

| Parameter | Value |

|---|---|

| Bioavailability | < 5% (Systemic) |

| Protein Binding | N/A (Inorganic) |

| Half-life | Variable (Local tissue residence) |

| Tmax | 15-30 minutes (Local) |

| Metabolism | Reticuloendothelial processing |

| Excretion | Minimal (Fecal/Renal trace) |

• Molecular Formula: FeS₂
• Molecular Weight: 119.98 g/mol
• Solubility: Insoluble in water; soluble in concentrated nitric acid.
• Structure: A cubic crystal system where iron atoms are coordinated to disulfide groups. In extract form, it is processed into a sterile aqueous or glycerinated suspension.

Ferrous Disulfide belongs to the class of Non-Standardized Allergenic Extracts. It is grouped with other environmental and mineral substances used by allergists to diagnose and treat hypersensitivity disorders that do not have a standardized 'AU' (Allergy Unit) or 'BAU' (Bioequivalent Allergy Unit) rating.